Literature DB >> 9364472

Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells.

H Boleti1, I R Coe, S A Baldwin, J D Young, C E Cass.   

Abstract

Equilibrative nucleoside transport processes in mammalian cells are categorized as either nitrobenzylthioinosine (NBMPR)-sensitive (es) or NBMPR-insensitive (ei). Inhibition of the es process arises from binding of NBMPR to a high-affinity site(s) on the es transporter that can be identified by photoaffinity labeling with [3H]NBMPR. This study examined the equilibrative nucleoside transport processes of cultured human erythroleukemia (K562) cells. The presence of NBMPR binding sites (4.8 +/- 0.9 x 10(5)/cell, Kd = 0.3 nM), together with the identification of polypeptides by specific photolabeling of membranes with [3H]NBMPR, indicated that K562 cells possess es nucleoside transporters (ca 500,000 copies/cell). The photolabeled polypeptides of K562 cells migrated with lower relative mobility (peak M(r) value, 63,000) than did those of human erythrocytes (peak M(r) value, 53,000). This difference in apparent M(r) was abolished by prolonged treatment of membrane proteins with N-glycosidase F, suggesting that equilibrative nucleoside transport in K562 cells and erythrocytes is mediated by the same, or a closely related, es isoform. A cDNA encoding the es nucleoside transporter of human placenta (termed hENT1) was recently isolated by a strategy based on the N-terminal sequence of the es transporter of human erythrocytes. hENT-like mRNA species were detected in K562 cells, as well as in several other human cell lines of neoplastic origin (A459, G361, HeLa, HL-60, Molt-4, Raji, SW480), by high-stringency northern analysis with a placental hENT1 probe. A cDNA that encoded a protein identical to hENT1 was isolated by reverse transcriptase polymerase chain reaction with primers specific for hENT1. NBMPR inhibited zero-trans influx of 3H-labeled adenosine, uridine and thymidine by 50% (IC50 values) at 0.4-1.0 nM, confirming the presence of an NBMPR-sensitive (es) transport process, which accounted for 80-90% of total transport activity. The remaining component was identified as the equilibrative NBMPR-insensitive (ei) transport process since it: (i) exhibited low (IC50 > 1.0 microM) sensitivity to NBMPR; (ii) was not concentrative; and (iii) was unchanged by elimination of the sodium gradient. The kinetic parameters (determined at 37 degrees C) for the es- and ei-mediated processes differed markedly. Values for transport of uridine by the es- and ei-mediated processes were, respectively: K(m) = 229 +/- 39 and 1077 +/- 220 microM; Vmax, 186 +/- 31 and 40 +/- 5 pmol/microliter cell water/sec. Values for transport of adenosine by the es and ei-mediated processes were, respectively, 61 +/- 9 and 133 +/- 17 microM; Vmax, 70 +/- 5 and 23 +/- 8 pmol/microlitere cell water/sec. The ei-mediated process, although small, was of pharmacologic importance since K562 cells could not be protected by NBMPR (10 microM) from the cytotoxic effects of tubercidin (7-deazaadenosine).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9364472     DOI: 10.1016/s0028-3908(97)00136-6

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  18 in total

1.  The plasma membrane permease PfNT1 is essential for purine salvage in the human malaria parasite Plasmodium falciparum.

Authors:  Kamal El Bissati; Rachel Zufferey; William H Witola; Nicola S Carter; Buddy Ullman; Choukri Ben Mamoun
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-02       Impact factor: 11.205

2.  Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.

Authors:  Shuiying Hu; Hongmei Niu; Hiroto Inaba; Shelley Orwick; Charles Rose; John C Panetta; Shengping Yang; Stanley Pounds; Yiping Fan; Christopher Calabrese; Jerold E Rehg; Dario Campana; Jeffrey E Rubnitz; Sharyn D Baker
Journal:  J Natl Cancer Inst       Date:  2011-04-12       Impact factor: 13.506

3.  Functional production and reconstitution of the human equilibrative nucleoside transporter (hENT1) in Saccharomyces cerevisiae. Interaction of inhibitors of nucleoside transport with recombinant hENT1 and a glycosylation-defective derivative (hENT1/N48Q).

Authors:  M F Vickers; R S Mani; M Sundaram; D L Hogue; J D Young; S A Baldwin; C E Cass
Journal:  Biochem J       Date:  1999-04-01       Impact factor: 3.857

4.  Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta.

Authors:  M Griffiths; S Y Yao; F Abidi; S E Phillips; C E Cass; J D Young; S A Baldwin
Journal:  Biochem J       Date:  1997-12-15       Impact factor: 3.857

5.  Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945.

Authors:  Radhakrishna G Pillai; Martin Forster; Meg Perumal; Fraser Mitchell; Julius Leyton; Franklin I Aibgirhio; Oksana Golovko; Ann L Jackman; Eric O Aboagye
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

6.  Nucleoside Reverse Transcriptase Inhibitor Interaction with Human Equilibrative Nucleoside Transporters 1 and 2.

Authors:  Siennah R Miller; Raymond K Hau; Joseph L Jilek; Mark N Morales; Stephen H Wright; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2020-05-11       Impact factor: 3.922

7.  Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors.

Authors:  Wenwei Lin; John K Buolamwini
Journal:  J Med Chem       Date:  2007-07-18       Impact factor: 7.446

8.  Novel regulation of equlibrative nucleoside transporter 1 (ENT1) by receptor-stimulated Ca2+-dependent calmodulin binding.

Authors:  Alex Bicket; Pedram Mehrabi; Zlatina Naydenova; Victoria Wong; Logan Donaldson; Igor Stagljar; Imogen R Coe
Journal:  Am J Physiol Cell Physiol       Date:  2016-03-23       Impact factor: 4.249

9.  Predicting Drug Interactions with Human Equilibrative Nucleoside Transporters 1 and 2 Using Functional Knockout Cell Lines and Bayesian Modeling.

Authors:  Siennah R Miller; Xiaohong Zhang; Raymond K Hau; Joseph L Jilek; Erin Q Jennings; James J Galligan; Daniel H Foil; Kimberley M Zorn; Sean Ekins; Stephen H Wright; Nathan J Cherrington
Journal:  Mol Pharmacol       Date:  2020-12-01       Impact factor: 4.436

10.  Testicular disposition of clofarabine in rats is dependent on equilibrative nucleoside transporters.

Authors:  Siennah R Miller; Joseph L Jilek; Meghan E McGrath; Raymond K Hau; Erin Q Jennings; James J Galligan; Stephen H Wright; Nathan J Cherrington
Journal:  Pharmacol Res Perspect       Date:  2021-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.